Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy has been initiated.
August 8, 2019: Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress
August 7, 2019: Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors
August 6, 2019: Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team